Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8154MR)

This product GTTS-WQ8154MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF1A gene. The antibody can be applied in Dry eye (DE) syndrome research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001065.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7132
UniProt ID P19438.1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8154MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ251MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ6690MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ2497MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ14175MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ15971MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ11281MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ1319MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ9752MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW